Ionis Pharmaceuticals
IONS
383 hedge funds and large institutions have $6.8B invested in Ionis Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 121 increasing their positions, 113 reducing their positions, and 49 closing their positions.
152% more call options, than puts
Call options by funds: $88.4M | Put options by funds: $35M
12% more capital inflows, than outflows
Capital inflows: $731M | Capital outflows: $651M
4% more funds holding
Funds holding: 368 → 383 (+15)
1.08% more ownership
Funds ownership: 84.85% → 85.93% (+1.1%)
7% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 113
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$119M |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
+$94.5M |
| 3 |
BlackRock
New York
|
+$64M |
| 4 |
JP Morgan Chase
New York
|
+$57.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$40.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$239M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.2M |
| 4 |
Two Sigma Investments
New York
|
-$39.1M |
| 5 |
Renaissance Technologies
New York
|
-$36M |
IONS Hedge Fund Activity: Q4 2020 in Review
383 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2020, worth a combined $6.8B — up 21% from $5.62B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of IONS and 48 opened new positions — a net loss of 1 holder — while 113 trimmed existing stakes and 121 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $119M. The largest seller was Baillie Gifford & Co, cutting an estimated $239M.
- 383 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2020, up from 368 in Q3 2020.
- Funds reported $6.8B of Ionis Pharmaceuticals stock for Q4 2020, up 21% quarter-over-quarter.
- 48 funds opened new Ionis Pharmaceuticals positions in Q4 2020 and 49 closed out, a net change of -1 holder.
- The largest Ionis Pharmaceuticals buyer in Q4 2020 was T. Rowe Price Associates, an estimated $119M added.
- The largest Ionis Pharmaceuticals seller in Q4 2020 was Baillie Gifford & Co, an estimated $239M sold.
Based on aggregated 13F filings for Q4 2020.